Molecular Insight Pharmaceuticals, Inc. and MDS Nordion Enter Manufacturing Agreement for Cardiac Molecular Imaging Pharmaceutical Zemiva(TM).CAMBRIDGE, Mass. -- Molecular Insight Pharmaceuticals, Inc. today announced that it has entered into a six-year, renewable agreement for the commercial manufacture and supply of Zemiva (iodofiltic acid I 123). Zemiva is a molecular imaging pharmaceutical under development by Molecular Insight for the diagnosis of cardiac ischemia, or insufficient blood flow to the heart. Molecular Insight's initial target market for Zemiva is for the diagnosis of cardiac ischemia in the emergency department setting, where an estimated five to eight million patients in the United States United States, officially United States of America, republic (2005 est. pop. 295,734,000), 3,539,227 sq mi (9,166,598 sq km), North America. The United States is the world's third largest country in population and the fourth largest country in area. present each year with chest pain. Further terms of the agreement were not disclosed. "We believe that this is an important agreement for the long-term commercial supply of Zemiva, our lead product candidate," said David Barlow David Barlow was a fictional character in UK Soap Opera Coronation Street.Played by Alan Rothwell. He married Irma Ogden in 1965 and a year later they bought the Corner Shop from Lionel Petty. David died in 1970 in a car crash in Australia. , Chairman and Chief Executive Officer of Molecular Insight. "MDS MDS, n See temporomandibular pain-dysfunction syndrome. MDS 1 Maternal deprivation syndrome, see there 2 Myelodysplastic syndrome, see there Nordion has been an outstanding partner during Zemiva's clinical development program and we look forward to continuing to work with the company." About Molecular Insight Pharmaceuticals, Inc. Molecular Insight Pharmaceuticals is a biopharmaceutical company focused on the research, development and commercialization of innovative molecular imaging pharmaceuticals and targeted radiotherapeutics. The company's product candidates target markets with significant unmet needs in cardiology, oncology, and neurology. Molecular Insight's lead product candidate, Zemiva (iodofiltic acid I 123) is in development as a molecular imaging pharmaceutical for the diagnosis of insufficient blood flow to the heart, or cardiac ischemia. The company's second lead product candidate, Ultratrace(TM) MIBG MIBG Metaiodobenzylguanidine , is in development for the diagnosis and treatment of neuroendocrine tumors Neuroendocrine Tumors Definition Neuroendocrine tumor refers to the type of cell that a tumor grows from rather than where that tumor is located. . Molecular Insight Pharmaceuticals is based in Cambridge, Massachusetts This article is about the city of Cambridge in Massachusetts. For the English university town, see Cambridge, England. For other places, see Cambridge (disambiguation). Cambridge, Massachusetts is a city in the Greater Boston area of Massachusetts, United States. . The company's website is: www.molecularinsight.com. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion